These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1116 related articles for article (PubMed ID: 20299607)

  • 1. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure).
    Boccanelli A; Cacciatore G; Mureddu GF; de Simone G; Clemenza F; De Maria R; Di Lenarda A; Gavazzi A; Latini R; Masson S; Porcu M; Vanasia M; Gonzini L; Maggioni AP
    J Cardiovasc Med (Hagerstown); 2007 Sep; 8(9):683-91. PubMed ID: 17700397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Suzuki G; Morita H; Mishima T; Sharov VG; Todor A; Tanhehco EJ; Rudolph AE; McMahon EG; Goldstein S; Sabbah HN
    Circulation; 2002 Dec; 106(23):2967-72. PubMed ID: 12460880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?
    Weir RA; Mark PB; Petrie CJ; Clements S; Steedman T; Ford I; Ng LL; Squire IB; Wagner GS; McMurray JJ; Dargie HJ
    Am Heart J; 2009 Jun; 157(6):1088-96. PubMed ID: 19464421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
    J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.
    Colucci WS; Kolias TJ; Adams KF; Armstrong WF; Ghali JK; Gottlieb SS; Greenberg B; Klibaner MI; Kukin ML; Sugg JE;
    Circulation; 2007 Jul; 116(1):49-56. PubMed ID: 17576868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure.
    Chan AK; Sanderson JE; Wang T; Lam W; Yip G; Wang M; Lam YY; Zhang Y; Yeung L; Wu EB; Chan WW; Wong JT; So N; Yu CM
    J Am Coll Cardiol; 2007 Aug; 50(7):591-6. PubMed ID: 17692742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
    Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
    J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).
    Deswal A; Richardson P; Bozkurt B; Mann DL
    J Card Fail; 2011 Aug; 17(8):634-42. PubMed ID: 21807324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
    Fraccarollo D; Galuppo P; Schmidt I; Ertl G; Bauersachs J
    Cardiovasc Res; 2005 Jul; 67(1):97-105. PubMed ID: 15949473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
    Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
    Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis.
    Stewart RA; Kerr AJ; Cowan BR; Young AA; Occleshaw C; Richards AM; Edwards C; Whalley GA; Freidlander D; Williams M; Doughty RN; Zeng I; White HD;
    Am Heart J; 2008 Aug; 156(2):348-55. PubMed ID: 18657667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
    Gheorghiade M; Khan S; Blair JE; Harinstein ME; Krum H; Mukherjee R; Pitt B;
    Am Heart J; 2009 Sep; 158(3):437-43. PubMed ID: 19699868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction.
    Weir RA; Tsorlalis IK; Steedman T; Dargie HJ; Fraser R; McMurray JJ; Connell JM
    Eur J Heart Fail; 2011 Dec; 13(12):1305-13. PubMed ID: 21940729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.
    Mottram PM; Haluska B; Leano R; Cowley D; Stowasser M; Marwick TH
    Circulation; 2004 Aug; 110(5):558-65. PubMed ID: 15277317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms.
    Vizzardi E; Sciatti E; Bonadei I; D'Aloia A; Tartière-Kesri L; Tartière JM; Cohen-Solal A; Metra M
    Clin Res Cardiol; 2015 Dec; 104(12):1078-87. PubMed ID: 26058790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials.
    Li X; Qi Y; Li Y; Zhang S; Guo S; Chu S; Gao P; Zhu D; Wu Z; Lu L; Shen W; Jia N; Niu W
    Circ Heart Fail; 2013 Mar; 6(2):156-65. PubMed ID: 23400891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure.
    Vizzardi E; D'Aloia A; Giubbini R; Bordonali T; Bugatti S; Pezzali N; Romeo A; Dei Cas A; Metra M; Dei Cas L
    Am J Cardiol; 2010 Nov; 106(9):1292-6. PubMed ID: 21029826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.